Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Differences in age-related retinal and cortical atrophy rates in multiple sclerosis
Multiple Sclerosis
S26 - MS Imaging (1:12 PM-1:24 PM)
002

It is critical to understand if neuroaxonal loss in MS is continuously linear or declines with time.

To assess and compare rates of neurodegeneration in retina and brain throughout the MS disease course in a well-phenotyped longitudinal cohort.


We analyzed 598 MS patients (mean age 45.3±11 yrs; dz duration 11.6±9.7 yrs), who underwent longitudinal OCT imaging annually for a period of 4.5±2.4 years. Longitudinal MRI scans (study period of 10±3.4 yrs) were available from 434 patients (mean age 41.8±9.6 yrs; dz duration 8±8.3 yrs). Primary outcome parameters were macular ganglion cell–inner plexiform layer (GCIPL) volume and cortical gray matter (CGM) volume.

To evaluate the rate of loss, linear mixed-effects modeling with subject-specific intercepts and slopes were fitted using restricted maximum likelihood estimation. The association between the slope of decline in the anatomical structure and the age of entry in the cohort (categorized by the MRI cohort’s age quartiles) was assessed by linear regression models

The rate of CGM volume loss declined minimally with increasing age of study entry (ASE):1.3%/yr ASE<35yrs; 1.1%/yr ASE=35-41yrs;0.97%/yr ASE=41-49; and 0.9%/yr ASE>49 years. The rate of GCIPL thinning was highest in patients in the youngest ASE quartile, fell by nearly 50% in the following ASE quartile and then stabilized across ASE:0.7%/yr for ASE<35yrs; 0.29% for ASE=35-41yrs ; 0.34% for ASE=41-49yrs; 0.33% for ASE>49yrs.

An age-dependent reduction in rates of retinal and cortical volume loss during RRMS suggests deceleration in neurodegeneration in the earlier period of disease and further suggests that the period of greatest inflammatory activity is also the period with the greatest neuroaxonal loss. The observed difference in neurodegeneration between the CGM and retina could be due to differences in the architecture of the tissues, varying susceptibility to degenerative injury or differences in the sensitivity and specificity of OCT and MRI in detecting tissue atrophy.

Authors/Disclosures
Christian Cordano, MD, PhD (UCSF)
PRESENTER
Dr. Cordano has nothing to disclose.
Bardia Nourbakhsh, MD (Johns Hopkins University) The institution of Dr. Nourbakhsh has received research support from Genentech. The institution of Dr. Nourbakhsh has received research support from national MS Society . The institution of Dr. Nourbakhsh has received research support from Department of Defense. The institution of Dr. Nourbakhsh has received research support from NIH.
Hao Yiu No disclosure on file
Nico Papinutto No disclosure on file
No disclosure on file
Ahmed Abdelhak, MD (UCSF Weill Institute of Neuroscience) The institution of Dr. Abdelhak has received research support from German Multiple Sclerosis Society.
Frederike Cosima Oertel, MD (University of California, San Francisco) The institution of Dr. Oertel has received research support from AAN. The institution of Dr. Oertel has received research support from Hertie Foundation. Dr. Oertel has received personal compensation in the range of $500-$4,999 for serving as a Recipient (Travel Grant) with ECTRIMS. Dr. Oertel has received personal compensation in the range of $500-$4,999 for serving as a Recipient (Travel Grant) with NMSS. Dr. Oertel has received personal compensation in the range of $500-$4,999 for serving as a Recipient (Travel Grant) with ACTRIMS.
Alexandra Beaudry-richard (UCSF) No disclosure on file
No disclosure on file
No disclosure on file
Daniel Bennett (UCSF School Of Medicine) No disclosure on file
No disclosure on file
No disclosure on file
Stephen L. Hauser, MD (UCSF Weill Institute for Neurosciences) Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NGM Bio. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BD. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pheno Therapeutics. Dr. Hauser has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Accure. Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alector. Dr. Hauser has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Annexon. Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Neurona. Dr. Hauser has a non-compensated relationship as a Clinical Trial/Primary Investigator with Roche that is relevant to AAN interests or activities. Dr. Hauser has a non-compensated relationship as a Clinical Trial/Primary Investigator with Novartis that is relevant to AAN interests or activities.
Bruce A. Cree, MD, PhD, MCR, FAAN (UCSF, Multiple Sclerosis Center) The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Autobahn. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avotres. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon. Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neuron23. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Pharma. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal/Sandoz. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kyverna. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Pharma. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. The institution of Dr. Cree has received research support from Genentech. The institution of Dr. Cree has received research support from Kyverna. Dr. Cree has received publishing royalties from a publication relating to health care.
No disclosure on file
Roland G. Henry, PhD (University of California, San Francisco) Dr. Henry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MEDDAY. Dr. Henry has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Henry has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Henry has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi/Genzyme.
Ari Green, MD (UCSF) Dr. Green has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pipeline Therapeutics. Dr. Green has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bionure. Dr. Green has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. The institution of Dr. Green has received research support from NINDS. The institution of Dr. Green has received research support from NMSS. The institution of Dr. Green has received research support from NIA. The institution of Dr. Green has received research support from Adelson Research Foundation. Dr. Green has received intellectual property interests from a discovery or technology relating to health care. Dr. Green has received personal compensation in the range of $500-$4,999 for serving as a Study Section with NINDS. Dr. Green has a non-compensated relationship as a Author with Viela Bio that is relevant to AAN interests or activities.